Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics Ltd. Announces Results for the Three and Nine Months Ended March 31, 2017

Marketwired May 25, 2017

Revive Therapeutics Ltd. Grants Incentive Stock Options

Marketwired April 12, 2017

Revive Therapeutics Provides Corporate Update

Marketwired March 29, 2017

Revive Therapeutics Appoints Dr. Scott Friedman, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases

Marketwired March 22, 2017

Revive Therapeutics Appoints Dr. Yanlin Wang, MD, PhD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Kidney Diseases

MarketWire Canada March 8, 2017

Revive Therapeutics Announces Initiation of Research Discovery Program of Cannabinoid-Based Therapies Targeting Liver Diseases

MarketWire Canada March 1, 2017

Revive Therapeutics Ltd. Announces Results for the Three and Six Months Ended December 31, 2016

MarketWire Canada February 28, 2017

Revive Therapeutics Announces Term Sheet with InMed Pharmaceuticals for the Discovery and Development of Cannabinoid-Based Therapy Targeting Kidney Diseases

MarketWire Canada February 22, 2017

Revive Therapeutics Announces Expansion into Cannabinoid-Based Therapies Targeting Liver Diseases

MarketWire Canada February 16, 2017

Revive Therapeutics Announces Initiation of a Phase 2 Study of REV-004 (Bucillamine) in Cystinuria

MarketWire Canada February 7, 2017

Revive Therapeutics Appoints Dr. Pritesh Kumar as Scientific Advisor for Cannabinoid-Based Therapeutics

MarketWire Canada January 24, 2017

Revive Therapeutics Engages Massachusetts General Hospital for Cystinuria Phase 2 Study

MarketWire Canada January 12, 2017

Revive Therapeutics Engages NYU School of Medicine for Cystinuria Phase 2 Study

MarketWire Canada December 21, 2016

Revive Therapeutics Ltd. Announces Positive Study Results in Rett Syndrome

MarketWire Canada December 6, 2016

Revive Therapeutics Ltd. Announces Results for the Three Months Ended September 30, 2016

MarketWire Canada November 24, 2016

Revive Therapeutics Ltd. Names Dr. David S. Goldfarb, MD, as Principal Investigator for Cystinuria Phase 2 Study

MarketWire Canada November 2, 2016

Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2016

MarketWire Canada October 20, 2016

Revive Completes $1,500,000 Non-Brokered Private Placement

MarketWire Canada August 18, 2016

Revive Therapeutics Ltd. Announces US FDA Acceptance of IND of Bucillamine for the Treatment of Cystinuria

MarketWire Canada July 6, 2016

Revive Therapeutics Announces New CEO and New President

MarketWire Canada July 5, 2016